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increasedprescribingof opioidObjectives: To examine trends in codeine-related mortality rates in
Australia, and the clinical and toxicological characteristics of
codeine-related deaths.
Design and setting: Analysis of prospectively collected data from the
National Coronial Information System on deaths where codeine toxicity was
determined to be an underlying or contributory cause of death. The study
period was 2000e2013.
Main outcome measures: Population-adjusted numbers (per million
persons) of (1) codeine-related deaths, classified by intent (accidental or
intentional); and (2) heroin- and Schedule 8 opioid-related deaths (as a
comparator).
Results: The overall rate of codeine-related deaths increased from 3.5 per
million in 2000 to 8.7 per million in 2009. Deaths attributed to accidental
overdoses weremore common (48.8%) than intentional deaths (34.7%), and
their proportion increased during the study period. High rates of prior comorbid
mental health (53.6%), substance use (36.1%) and chronic pain (35.8%)
problems were recorded for these deaths. For every two Schedule 8
opioid-related deaths in 2009, there was one codeine-related death. Most
codeine-related deaths (83.7%) were the result of multiple drug toxicity.
Conclusions: Codeine-related deaths (with and without other drug
toxicity) are increasing as the consumption of codeine-based products
increases. Educational messages are needed to better inform the
public about the potential harms of chronic codeine use, especially in the
context of polypharmacy.Ranalgesics during the past
decade has resulted in rises in mortal-
ity caused by overdose in many
developed countries.1-4 One opioid
analgesic that has not received much
attention is codeine, which is often
used in the belief that it is a weaker
opioid, less likely to cause dependence
and fatal overdose than morphine, for
example. It is important to test this
assumption, as more codeine is
consumed in the United Kingdom,
Canada and Australia than any other
opioid.5Codeine isalsooneof themost
accessible opioids, available without
prescription (over-the-counter) in the
UK, Canada, France, New Zealand
and Australia.6
Concerns have been raised in a
number of countries about the
adverse consequences of codeine use.
Use among children has been limited
in several countries, and there have
been calls to completely remove co-
deine from the market.7,8
There are documented risks associ-
ated with prolonged codeine use. It
can produce tolerance, which may
lead to escalating doses and depen-
dence, particularly among patients
whose pain is notwellmanaged.6,9-11
Risks are also associated with prod-
ucts that combine codeine with other
analgesics. Prolonged use of high-
dose codeineeibuprofen combina-
tions has been linked with gastroin-
testinal disease and renal failure,12-14
while paracetamolecodeine com-
binations have been linked with
hepatotoxicity.15,16 Dose escalation,
which commonly occurs in the
course of long-term codeine use, also
increases the risks of side effects
associated with ibuprofen and
paracetamol.6
There are also concerns about the
variability with which codeine is
metabolised. Codeine is converted to
morphine in the liver by the enzymecytochrome P450 2D6.8,17 This
enzyme is subject to genetic variation.
Some individuals (about 7%e10% of
the European white population) are
poor metabolisers, meaning that little
codeine is converted into morphine
and analgesia is ineffective. About
5% of the white population are ul-
trarapid metabolisers, meaning there
is greater conversion to morphine
and increased risk of adverse events,
such as respiratory depression and
fatal overdose.11
Codeine-related mortality has in-
creased in a number of countries,
including the UK,18 and case series of
codeine deaths have been reported in
the United States,19 the UK and
Australia.20,21 Case studies in the US
have also documented deaths caused
by thepostoperative use of codeine in
children.19
Analysis of mortality data provides
an opportunity to systematically
examine the characteristics ofMJA 203 (7)codeine users who experience the
most severe adverse consequence, a
fatal overdose. In this article, we
present data on codeine-related
mortality in Australia, examining:
 rates of accidental and inten-
tional codeine-related mortality;
 rates of heroin- and Schedule 8
opioid-related mortality;
 demographic, mental and physical
health characteristics of codeine-
related mortality cases; and
 the circumstances of these deaths,
including the presence of other
drugs and the origin of codeine
products consumed before death
(prescribed or obtained over the
counter).
Methods
Coding of deaths
We searched the National Coronial
Information System (NCIS) for deathsj 5 October 2015 299.e1
299.e2
Researchduring the period2001e2013 inwhich
codeine toxicity or overdose was
recorded as a direct or a contributory
cause of death. The NCIS is a central-
ised online record of deaths reported
to the coroner. The NCIS contains
coronial files from all states and terri-
tories in Australia and from New
Zealand, but this article reviews only
deaths in Australia, where routine
toxicological screening is conducted
after most drug-related deaths. Find-
ings on the role of particular sub-
stances in these deaths are made by a
coroner, often on the advice of forensic
toxicologists.
Searches were conducted using the
category “pharmaceutical substance
for human use”, leaving the des-
criptor field for these substances
blank, or specifying the subcategory
as “analgesic, antipyretic, antirheu-
matic”, and then further specifying
“codeine”. Keyword searches were
also conducted in findings docu-
ments, yielding additional cases.
The focus of our study concerned
codeine-related deaths, and the
methodsoutlined inAppendix1were
used to extract cases of interest. Ap-
pendix 2 outlines themethodsused to
distinguishbetweendeaths involving
codeine only, and those involving
both codeine andmorphine. It can be
technically difficult to distinguish
between deaths caused by codeine,
heroin or morphine because of the
manner in which these drugs are
metabolised. Codeine is metabolised
to morphine, and codeine can also be
produced as a metabolite of heroin.
Caseswere removed from the dataset
in which there was clear evidence
that heroin had been consumed
before death (eg, the detection of
6-monacetylmorphine, or eyewitness
reports ofheroinuse), aswere those in
which there was no evidence of co-
deine consumption.
Codeine-related deaths were there-
fore defined as deaths where codeine
was detected and codeine toxicity
contributed to death, including
deaths attributed to multiple drug
toxicity.
During the period 2000e2013, we
identified a total of 1444 deaths in
which codeine toxicity was aMJA 203 (7) j 5 October 2015contributory cause of death. Seven
deaths were excluded because, on
closer examination, they were not
clearly drug-related (eg, the cause of
death was recorded as gunshot
wound, with codeine toxicity as a
contributory cause), or because co-
deine was recorded in the toxicolog-
ical report but was not considered to
be a contributory cause of death. The
remaining 1437 cases were included
in our analysis.Coding of additional variables
Several variables of interest were not
consistently coded in the NCIS
because of differing jurisdictional
procedures. These included whether
the deceased had a recorded history
of injecting drug use, chronic pain,
mental health problems or substance
use problems (including misuse and
dependence). In addition, where
possible, we recorded the brand
name of the codeine consumed (eg,
Panadeine forte, containing 500 mg
paracetamol and 30 mg codeine
phosphate; Panadeine, containing500
mg paracetamol and 8 mg codeine
phosphate; Nurofen Plus, containing
200 mg ibuprofen and 12.8 mg co-
deine phosphate), and these were
separated into over-the-counter
(OTC) and prescription products. All
these variables were coded using in-
formation contained in police, au-
topsy and findings reports.Data analysis
Analyses were conducted with SPSS
version 22 (IBM). Numbers of deaths
per million population were calcu-
lated using Australian Bureau of
Statistics estimates of the resident
population for 30 June of each year.
Differences in the intent characteris-
tics of cases (accidental, intentional,
not determined) were analysed by
multinomial logistic regression.
We present data on the characteris-
tics of cases aswell as onwhether the
deathswere intentional or accidental
for the period 2000e2013. We pre-
sent trends in codeine-related deaths
by intent and as rates per million
population for the period 2000e2009
only. As data for 2010e2013 were
likely to be incomplete (some caseswould not yet have been finalised on
the NCIS), trends for the segment
2010e2013 could not be reliably
determined.
Trends over time were tested using
Poisson regression modelling. The
outcome variable for the model was
intent (accidental or intentional).
Findings were considered significant
when P < 0.05.
In order to place codeine-related
deaths into the broader context of
opioid-related deaths, NCIS data for
other opioid-related deaths are also
presented here; that is, where heroin,
Schedule 8 opioids (including
buprenorphine, fentanyl, metha-
done, morphine or oxycodone) or
multiple opioid toxicity were identi-
fied as underlying or contributory
causes of death.Ethics approval
Ethics approval for analysis of NCIS
datawas granted by theUniversity of
New South Wales Human Research
Ethics Committee (HC 13081) and
the Department of Justice Human
Research Ethics Committee (CF/12/
22067).Results
Poisson regression modelling indi-
cated that the rate of all codeine-
related deaths increased during the
period 2000e2009 by 0.5 deaths per
million persons per year, from 3.5
deaths per million in 2000 to 8.7 per
million in 2009 (P < 0.01). The rate of
deaths due to accidental codeine
overdose also increased signifi-
cantly, with a 9.3% (95% CI, 5.4%e
13.5%) increase recorded each year,
from 1.8 to 5.1 deaths per million
persons (P < 0.001; Box 1). There was
no significant trend in intentional
codeine overdose deaths during
2000e2009.
Deaths attributed to heroin, Schedule
8 opioids, and multiple opioid
toxicity were more common than
codeine-related deaths (Box 2). The
rate was highest for heroin- and
Schedule 8 opioid-related deaths, at
about 16 deaths per million persons
for each in 2009.
1 Rates of codeine-related death by intent, per million population,
2000e2009
ResearchMost codeine-related deaths during
2000e2013 (1201, 83.7%) were
attributed to multiple drug toxicity.
A small proportion (113, 7.8%) were
specifically attributed to codeine
toxicity (105, codeine toxicity alone;
six, combined carbon monoxide and
codeine toxicity; two, combined
alcohol and codeine toxicity). The
remaining 123 deaths (8.5%) were
attributed to other underlying cau-
ses, such as coronary heart disease,
cardiovascular conditions and other
drug toxicity (Box 3). The rate of in-
crease in the number of deaths spe-
cifically attributed to codeine was
greater than the rate of increase in the
number of deaths attributed to mul-
tiple drug toxicity (data not shown).
The numbers of codeine-related
deaths among men and women2 Rates of codeine-related death, pe
with other opioid-related deaths, 2were similar, and the mean age at
deathwas 45 years (Box 3). Just under
half the deaths (701, 48.8%) were
attributed to accidental overdose and
a third (499, 34.7%) to intentional self-
harm. Intent was not determined in
the remaining 237 deaths (16.5%).
More than half (53.6%) of the cases of
codeine-related death included a
history of mental health problems,
36.1% a history of substance use
problems (including misuse and
dependence), 35.8% a history of
chronic pain, 16.3% a history of
injecting drug use, and 2.7% a history
of cancer.
In 59.9% of cases (861), there was no
information about whether the co-
deine consumed before death was
prescribed or obtained over ther million population, compared
000e2009counter. Where the name or specific
details of the codeine product were
available, a prescription codeine
product (most commonly Panadeine
forte) was recorded in 59.9% of cases
(343 of 572), and OTC codeine prod-
ucts were recorded in the remaining
229 cases.
Deaths caused by accidental
versus intentional overdose
Those who had intentionally over-
dosed were more likely to be older,
female and have a history of mental
health problems, and were less likely
to have a history of substance use
problems, chronic pain or injecting
drug use (Box 3). Mental health
problems were common in those
involved in intentional deaths, and
the combination of chronic pain and
mental health problems were re-
corded for 25.7% of these cases
(Box 4).
A range of other drugsweredetected
during the toxicological investiga-
tion of these deaths. The most com-
mon were benzodiazepines (56.1%),
paracetamol, ibuprofen or doxyl-
amine (54.6%; indicative of the use
of combination codeine products),
antidepressants (37.8%) and alcohol
(25.9%). Combination codeine
products were significantly more
likely to be recorded in intentional
overdoses (65.1%) than in accidental
overdoses (48.6%; odds ratio [OR],
1.9; 95% CI, 1.5e2.5). It was signifi-
cantly less likely that pharmaceu-
tical opioids (17.6%;OR, 0.4; 95%CI,
0.3e0.5) or illicit drugs (6.8%; OR,
0.4; 95% CI, 0.2e0.5) were detected
in intentional overdoses than in
those who accidentally overdosed
(35.5% and 16.4%, respectively)
(Box 5).
Discussion
The rate of codeine-related deaths
increased significantly between
2000 and 2009, from 3.5 to 8.7 deaths
per million population. The in-
crease was primarily driven by an
increase in accidental deaths. A
potential driver may have been the
introduction in Australia of OTC
products containing larger amounts
of codeine, including codeine com-
bined with ibuprofen.22,23 The rateMJA 203 (7) j 5 October 2015 299.e3
4 Recorded comorbid conditions associated with codeine-related
deaths
A B
3 Characteristics of the deaths in which codeine toxicity was a contributory factor, 2000e2013
Total
deaths
Accidental
overdose
Intentional
overdose
Intentional v
accidental, OR
(95% CI)
Intent not
determined
Not determined v
accidental, OR
(95% CI)
Number (%) 1437 701 (48.8%) 499 (34.7%) 237 (16.5%)
Underlying cause of death
Mixed drug toxicity 1201 (83.7%) 617 (88.0%) 418 (83.8%)* 0.7 (0.5e0.9) 166 (70.0%)‡ 0.3 (0.2e0.4)
Codeine toxicity 113 (7.8%) 54 (7.7%) 33 (6.6%) 0.7 (0.5e1.2) 26 (11.0%) 1.4 (0.8e2.2)
Other 123 (8.5%) 30 (4.1%) 48 (9.6%)‡ 2.4 (1.5e3.8) 45 (19.0%)‡ 5.3 (3.2e8.7)
Sex, female 717 (49.9%) 322 (45.9%) 268 (53.7%)† 1.3 (1.1e1.7) 127 (53.6%)* 1.4 (1.1e1.8)
Mean age, years (range) 45 (14e93) 43 (14e92) 46 (15e93)‡ 1.02 (1.01e1.03) 47 (18e92)‡ 1.02 (1.01e1.03)
Age group
14e19 years 16 (1.1%) 7 (1.0%) 8 (1.6%) NA NP NA
20e29 years 154 (10.7%) 88 (12.6%) 50 (10.0%) 16 (6.8%)
30e39 years 354 (24.6%) 202 (28.8%) 100 (20.0%) 52 (21.9%)
40e49 years 415 (28.9%) 191 (27.2%) 149 (29.9%) 75 (31.6%)
50e59 years 301 (20.9%) 143 (20.4%) 101 (20.2%) 57 (24.1%)
60e69 years 125 (8.7%) 47 (6.7%) 56 (11.2%) 22 (9.3%)
 70 years 72 (5.0%) 23 (3.3%) 35 (7.1%) NP
History of mental
health problems
771 (53.6%) 337 (48.1%) 329 (65.9%)‡ 2.1 (1.6e2.7) 105 (44.3%) 0.9 (0.6e1.2)
History of substance
use problems
519 (36.1%) 329 (46.9%) 106 (21.2%)‡ 0.3 (0.2e0.4) 84 (35.4%)† 0.6 (0.4e0.8)
History of chronic pain 514 (35.8%) 275 (39.2%) 168 (33.7%)* 0.7 (0.6e0.9) 71 (30.0%)* 0.6 (0.4e0.9)
History of injecting drug use 234 (16.3%) 167 (23.9%) 38 (7.6%)‡ 0.3 (0.1e0.4) 29 (12.2%)‡ 0.4 (0.3e0.7)
History of cancer 39 (2.7%) NP NP NA NP NA
OR ¼ odds ratio; NA ¼ not applicable; NP ¼ not published in order to protect confidentiality (small numbers). * P < 0.05, † P < 0.01, ‡ P < 0.001, compared with accidental overdose
category.u
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Researchof codeine-related deaths was
around half that of deaths attributed
to heroin and Schedule 8 opioids.
Two distinct populations were
detected. Those who had intention-
ally overdosedweremore likely to be
older, female and have a history of
mental health problems; those who
had accidentally overdosed were
more likely to have a history of sub-
stance use problems, chronic pain
and injecting drug use. These pat-
terns suggest that, in the accidental
deaths, there may be evidence of: (a)
codeine being used to top up pre-
scribed pain medication; (b) dose
escalation of codeine; and (c) the
development of codeine dependence.
These characteristics highlight a
complex patient population in need
of specialist services.
In cases where data were available,
most deaths involved people whoMJA 203 (7) j 5 October 2015had been prescribed codeine prod-
ucts, although a significant minority
(40.0%) had used OTC codeineproducts. The investigation of trends
in the sales of OTC codeine as
well as of codeine prescribing
5 Toxicology profile of other drugs involved in codeine deaths, by intent
Drug Total (n ¼ 1437)
Accidental
(n ¼ 701)
Intentional
(n ¼ 499)
Intentional v accidental,
OR (95% CI)
Not determined
(n ¼ 237)
Not determined v
accidental, OR
(95% CI)
Benzodiazepines 806 (56.1%) 422 (60.2%) 266 (53.3%)* 0.7 (0.6e0.9) 118 (49.8%)† 0.6 (0.4e0.8)
Paracetamol, ibuprofen,
doxylamine§
785 (54.6%) 341 (48.6%) 325 (65.1%)‡ 1.9 (1.5e2.5) 119 (50.2%) 1.1 (0.8e1.4)
Antidepressants, mood
stabilisers
544 (37.8%) 264 (37.7%) 207 (41.5%) 1.2 (0.9e1.5) 73 (30.8%) 0.7 (0.5e1.1)
Alcohol 372 (25.9%) 186 (26.5%) 128 (25.7%) 1.0 (0.7e1.2) 58 (24.5%) 0.9 (0.6e1.3)
Pharmaceutical opioids{ 401 (27.9%) 249 (35.5%) 88 (17.6%)‡ 0.4 (0.3e0.5) 64 (27.0%)* 0.7 (0.5e0.9)
Methadone 153 (10.6%) 115 (16.4%) 10 (2.0%) 28 (11.8%)
Oxycodone 159 (11.1%) 87 (12.4%) 46 (9.2%) 26 (11.0%)
Tramadol 118 (8.2%) 69 (9.8%) 37 (7.4%) 12 (5.1%)
Illicit drugs** 167 (11.6%) 115 (16.4%) 34 (6.8%)‡ 0.4 (0.2e0.5) 18 (7.6%)† 0.4 (0.2e0.7)
Cannabis 104 (7.2%) 68 (9.7%) 25 (5.0%) 11 (4.6%)
Amphetamines 69 (4.8%) 49 (7.0%) 9 (1.8%) 11 (4.6%)
OR ¼ odds ratio. * P < 0.05, † P < 0.01, ‡ P < 0.001, compared with accidental overdose category. § Indicative of the use of combination codeine products. { Includes methadone,
oxycodone, tramadol, fentanyl and buprenorphine. Fentanyl and buprenorphine numbers not shown to protect confidentiality. ** Includes cannabis, amphetamines, cocaine and
heroin. Heroin and cocaine not shown to protect confidentiality.u
Researchpatterns is warranted, and will assist
understanding patterns of codeine
consumption and related harms in
Australia.
Clinical implications
Our findings suggest the need for
different public health and clinical
strategies to prevent fatal intentional
and accidental codeine overdoses.
Suicide prevention strategies are
needed to reduce intentional overdose
deaths. A meta-analysis of suicide
prevention strategies24 indicated that
educating general practitioners has
significantly reduced suicide rates in a
number of countries. An increased
focus on screening for depression and
suicide risk is important when pre-
scribing codeine in primary care
encounters, which represent an im-
portant opportunity for interventions
that reduce the risk of suicide.
It may not be enough to change co-
deine prescribing practices, given
that codeine is available over the
counter in Australia. Pharmacists
mayhave an important role to play in
minimising harms6 by advising con-
sumers who purchase codeine prod-
ucts about the risks of chronicuse and
by encouraging them to seek further
medical advice.It is more challenging to reduce acci-
dental codeine overdoses, which are
more prevalent and increasing in
number. The high prevalence of sub-
stance use problems among those
who had accidentally overdosed
suggests the need for general practi-
tioners to screen for substance misuse
historywhen prescribing codeine.25,26
Patient education is also essential.
Patients receiving codeine should be
informed about the dangers of taking
too much codeine, and the increased
risk of fatal overdose if they combine
codeine with benzodiazepines and
other pharmaceutical opioids. The
risks associated with combination
products containing paracetamol
and codeine also need to be dis-
cussed. Evidence regarding the effi-
cacy of patient education is limited,27
and more Australian research would
be useful. Evaluative research in the
US has identified strategies that have
shown promise in reducing prob-
lematic patterns of pharmaceutical
use and of related harms.28,29 In
Australia, these strategies need to
include education at the point of
purchase of OTC codeine.
Finally, given the complex profile of
these cases and the high prevalence
of comorbid conditions, includingchronic pain, mental health and sub-
stance use problems, it is clearly
necessary to increase the capacity to
identify high-risk patients in primary
care and to respond more effectively
to their needs. Increasing the capacity
of specialist pain, addiction and
mental health treatment services in
Australia should also be a priority.
Limitations of our study
The online availability of autopsy
and coroner findings and of police
and toxicology reports differs
greatly between jurisdictions. Given
inconsistencies in reporting the
recorded histories of injecting drug
use, mental health problems and
substance use problems, we have
probably underestimated their
prevalence.
Missing data on the origin of codeine
products consumed prior to death
(prescribed or OTC) limits inferences
about the source of codeine in these
deaths, and hence inferences about
the extent to which the diversion of
prescribed codeine contributed to
these deaths. It also limits inferences
that can be drawn about the likely
impact of reducing OTC codeine
availability on the prevalence of
codeine-related mortality.MJA 203 (7) j 5 October 2015 299.e5
299.e6
ResearchThe variation in the way codeine is
metabolised, which affects the risk of
opioid toxicity, could not be analysed
in this study. Postmortem genetic
testing is not routinely undertaken in
Australia.
Limitations specific to the NCIS are
also important. These include case
completion and availability of data,
the accuracy of cause-of-death coding,
and the possibility that toxicological
findings may alter the determined
cause of death.30 The NCIS unit un-
dertakes quality assessment of all
closed cases to ensure that the most
accurate cause of death is coded.
Under-reporting of drug-related
deaths is a problem. In many cases,
the underlying medical cause of
death is deemed to be a respiratory
condition, such as asphyxia or
pneumonia. We attempted to
resolve this problem by searching
more broadly with “codeine” andMJA 203 (7) j 5 October 2015“morphine” as keywords, and by
using information on contributory
causes of death.
Conclusion
Increasing rates of codeine-related
mortality detected by our study
suggest it is important to systemati-
callymonitor codeine use and harms.
Given the ready availability of OTC
codeine in Australia, many people
consuming codeine are not easily
captured by existing monitoring
systems. In addition, many may not
be seen by doctors, increasing the
risks of their using codeine in non-
recommended ways that increase
the risk of harms.
Education about the dangers of tak-
ing too much codeine and the dan-
gers of polypharmacy is needed.
Pharmacists have an important role
in engaging with consumers who
purchase OTC codeine products.Finally, given the complex profile of
cases reported in this study, and the
high prevalence of comorbid condi-
tions, increasing the capacity of pri-
mary care screening processes, as
well as specialist pain, addiction and
mental health treatment services in
Australia is essential.
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